WHO ICTRP trial
A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in previously…
EUCTR2009-015297-36-FR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-015297-36-FR |
|---|---|
| Public title | A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in previously treated BRAF mutant metastatic melanoma |
| Scientific title | A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in previously treated BRAF mutant metastatic melanoma |
| Primary sponsor | GlaxoSmithKline Research & Development Limited |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;Germany;Italy |
| Conditions | BRAF Mutant Metastatic Melanoma MedDRA version: 12.1 Level: LLT Classification code 10027481 Term: Metastatic melanoma |
| Interventions | Product Name: gsk2118436 Product Code: GSK2118436 Pharmaceutical Form: Capsule* CAS Number: 1195768-06-9 Current Sponsor code: GSK2118436 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name… |
| Registration date | Jun 18, 2010 |
| Target size | 100 |
| Secondary IDs | BRF113710 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: